4D Molecular Therapeutics (FDMT) Return on Sales [ROS] (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted Return on Sales [ROS] of -2037.16% for Q2 2026, up 394336.17 percentage points from -396373.33% a year earlier and up 378.99 percentage points from the prior quarter.
4D Molecular Therapeutics (FDMT) Return on Sales [ROS] (2020 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at 4D Molecular Therapeutics was -214.24%, up 667440.31 percentage points year-over-year; for FY2025, it was -187.24%, up 507491.14 percentage points from FY2024.
- Annual Return on Sales [ROS] shows a five-year change of +229.04 percentage points (FY2020 to FY2025).
- In prior years, 4D Molecular Therapeutics' Return on Sales [ROS] was -507678.38% in FY2024 (-507133.73 pp), -544.65% in FY2023 (+2971.88 pp), -3516.52% in FY2022 (-3121.06 pp) and -395.46% in FY2021 (+20.82 pp).
- Quarterly Return on Sales [ROS] has run from a low of -5611700.00% in Q4 2024 to a high of 17.29% in Q4 2025 over five years.
- On a year-over-year basis, Return on Sales [ROS] has increased in each of the last five quarters, with an average year-over-year change of +114189.31 percentage points over the last eight quarters.
- The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q4 2025, with a gain of 5611717.29 percentage points; the weakest was Q4 2024, with a drop of 5611155.32 percentage points.
- According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -2416.15% (Q1 2026), 17.29% (Q4 2025) and -67983.33% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 37.40% |
| 10 | 4D Molecular Therapeutics | 1.01 Bn | -454.35 Mn | - | -2,037.16% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,037.16% |
| Mar 31, 2026 | -2,416.15% |
| Dec 31, 2025 | 17.29% |
| Sep 30, 2025 | -67,983.33% |
| Jun 30, 2025 | -396,373.33% |
| Mar 31, 2025 | -383,007.14% |
| Dec 31, 2024 | -5,611,700.00% |
| Sep 30, 2024 | -1,704,400.00% |
| Jun 30, 2024 | -849,120.00% |
| Mar 31, 2024 | -136,200.00% |
| Dec 31, 2023 | -544.68% |
| Sep 30, 2023 | -69.16% |
| Jun 30, 2023 | -13,446.03% |
| Mar 31, 2023 | -10,102.68% |
| Dec 31, 2022 | -2,303.13% |
| Sep 30, 2022 | -5,299.00% |
| Jun 30, 2022 | -17,546.91% |
| Mar 31, 2022 | -2,165.05% |
| Dec 31, 2021 | -26,917.39% |
| Sep 30, 2021 | -1,658.93% |
4D Molecular Therapeutics Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=FDMT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "FDMT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=FDMT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();